Government Speeds Up RSV Shot with 'Material Threat' Super Voucher
Published Date: 4/16/2026
Notice
Summary
The FDA just gave a big thumbs-up to MRESVIA, a vaccine fighting Respiratory Syncytial Virus, using a special priority review voucher designed for urgent medical threats. This means faster approval for important health products that protect us from serious diseases. Companies and patients benefit from quicker access to life-saving vaccines without extra costs or delays.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
RSV Vaccine Approved Using Priority Voucher
The FDA announced that MRESVIA (Respiratory Syncytial Virus Vaccine), approved May 31, 2024, redeemed a material threat medical countermeasure priority review voucher. That redemption uses the Priority Review Voucher process to speed review and enables earlier patient access to the approved vaccine.
Sponsors Eligible for Priority Vouchers
Under section 565A of the FD&C Act, the FDA is authorized to award material threat medical countermeasure (MCM) priority review vouchers to sponsors of approved MCM product applications that meet certain criteria. The FDA reports issuance of these vouchers and the approval of products redeeming them.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He didn’t respond to the FDA’s warning, so the ban started on May 15, 2026. If he wants to end the ban early, he can apply anytime, but must follow special rules to keep his info private.
2026-09533 — Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information
The FDA wants your help to improve tests that spot kidney damage caused by medicines. They’re asking researchers, doctors, and companies to share data by July 13, 2026, so they can make these kidney safety markers better and faster. This could lead to safer drugs and smarter health checks, benefiting patients and the medical community alike.
2026-09508 — Azodicarbonamide (ADA); Request for Information
The FDA is asking for info about azodicarbonamide (ADA), a chemical used in some foods and food packaging, to check if it’s still safe. Food makers, scientists, and anyone with data should share what they know by July 13, 2026. This review could lead to changes in how ADA is used, affecting food companies and possibly costs down the line.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This update affects drug makers and helps keep medicine safe by improving how side effects are tracked. You’ve got until July 13, 2026, to share your comments—no cost to join, just your voice!
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If renewed, the company can keep marketing them this way, with the comment period starting May 13, 2026.
2026-09507 — Butylated Hydroxytoluene (BHT); Request for Information
The FDA wants to know more about how butylated hydroxytoluene (BHT), a chemical used in food and food packaging, is being used and if it’s still safe. They’re asking companies, scientists, and the public to share any info by July 13, 2026. This could lead to changes in rules that affect food makers and might impact what’s allowed in your snacks and packaging.
Previous / Next Documents
Previous: 2026-07368 — Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)
The FDA just gave a big thumbs-up to AREXVY, a vaccine that helps protect kids from a serious lung virus called RSV. This approval used a special Rare Pediatric Disease Priority Review Voucher, which speeds up the review process for important medicines for rare childhood diseases. This means faster access to life-saving treatments for families, with no extra cost to the public.
Next: 2026-07370 — Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; MRESVIA (Respiratory Syncytial Virus Vaccine)
The FDA just gave the green light to MRESVIA, a new vaccine for Respiratory Syncytial Virus, using a special Rare Pediatric Disease Priority Review Voucher. This means faster approval for a medicine that helps kids with rare diseases, showing the FDA’s commitment to speedy access. The approval happened on June 12, 2025, and it’s a big win for families and vaccine makers alike!